Continuous hepatic arterial infusion with 5-fluorodeoxyuridine for treatment of colorectal metastases

R. Doci, P. Bignami, V. Quagliuolo, D. Civalleri, G. Simoni, M. Cosimelli, W. Craus, L. Gennari

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

5-Fluorodeoxyuridine (FdUrd) was delivered into the hepatic artery by means of totally implantable devices in 61 patients with hepatic metastases from colorectal cancer. The metastatic disease was staged according to Genari's staging system. FdUrd was infused continuously for 14 days every 28 days at a dose of 0.3 mg kg-1 day-1. Hepatic resection was carried out in addition to the infusion in 12 patients. Toxic effects were observed in 24 (39%) patients; 4 of them developed biliary sclerosis. Device-related complications were reported in 37 (60%) patients; failures affected ports (86%) more frequently than pumps (32%); the median duration of pumps and ports was 28 and 9 months respectively. Among non-resected patients complete disappearance of liver metastases and normalization of carcinoembryonic antigen (CEA) were observed in 2 patients, 1 of whom died from biliary sclerosis without evident tumor. A partial remission with a median duration of 7 months was assessed in 12 additional patients; thus the objective response rate (complete plus partial) was 30% in non-resected patients; the response was not clearly related to stage, or to other prognostic factors. Of 32 patients who showed regression or stable disease, 28 had documented progression, which in 18 (64%) was initially in extrahepatic sites. The median survival was 12 months, but it differed significantly according to stage. The presence of extrahepatic disease correlated with the worst prognosis. The survival of patients treated with a pump was no different from that of patients treated with a port. The study confirms that hepatic metastases from colorectal cancer can be controlled by arterial administration of FdUrd, but the benefit of treatment to survival is still to be demonstrated. The study also suggests that features of metastatic disease into and outside the liver can significantly affect survival. Thus, in evaluating the results of different treatments, the characteristics of metastases (i.e. the extent of hepatic involvement), should be taken into account.

Original languageEnglish
Pages (from-to)13-18
Number of pages6
JournalRegional Cancer Treatment
Volume3
Issue number1
Publication statusPublished - 1990

Fingerprint

Floxuridine
Neoplasm Metastasis
Liver
Therapeutics
Survival
Sclerosis
Colorectal Neoplasms
Equipment and Supplies
Poisons
Hepatic Artery
Carcinoembryonic Antigen

ASJC Scopus subject areas

  • Oncology
  • Pharmacology

Cite this

Doci, R., Bignami, P., Quagliuolo, V., Civalleri, D., Simoni, G., Cosimelli, M., ... Gennari, L. (1990). Continuous hepatic arterial infusion with 5-fluorodeoxyuridine for treatment of colorectal metastases. Regional Cancer Treatment, 3(1), 13-18.

Continuous hepatic arterial infusion with 5-fluorodeoxyuridine for treatment of colorectal metastases. / Doci, R.; Bignami, P.; Quagliuolo, V.; Civalleri, D.; Simoni, G.; Cosimelli, M.; Craus, W.; Gennari, L.

In: Regional Cancer Treatment, Vol. 3, No. 1, 1990, p. 13-18.

Research output: Contribution to journalArticle

Doci, R, Bignami, P, Quagliuolo, V, Civalleri, D, Simoni, G, Cosimelli, M, Craus, W & Gennari, L 1990, 'Continuous hepatic arterial infusion with 5-fluorodeoxyuridine for treatment of colorectal metastases', Regional Cancer Treatment, vol. 3, no. 1, pp. 13-18.
Doci, R. ; Bignami, P. ; Quagliuolo, V. ; Civalleri, D. ; Simoni, G. ; Cosimelli, M. ; Craus, W. ; Gennari, L. / Continuous hepatic arterial infusion with 5-fluorodeoxyuridine for treatment of colorectal metastases. In: Regional Cancer Treatment. 1990 ; Vol. 3, No. 1. pp. 13-18.
@article{dc880928e3b64f03b8307b33f5f1dd5c,
title = "Continuous hepatic arterial infusion with 5-fluorodeoxyuridine for treatment of colorectal metastases",
abstract = "5-Fluorodeoxyuridine (FdUrd) was delivered into the hepatic artery by means of totally implantable devices in 61 patients with hepatic metastases from colorectal cancer. The metastatic disease was staged according to Genari's staging system. FdUrd was infused continuously for 14 days every 28 days at a dose of 0.3 mg kg-1 day-1. Hepatic resection was carried out in addition to the infusion in 12 patients. Toxic effects were observed in 24 (39{\%}) patients; 4 of them developed biliary sclerosis. Device-related complications were reported in 37 (60{\%}) patients; failures affected ports (86{\%}) more frequently than pumps (32{\%}); the median duration of pumps and ports was 28 and 9 months respectively. Among non-resected patients complete disappearance of liver metastases and normalization of carcinoembryonic antigen (CEA) were observed in 2 patients, 1 of whom died from biliary sclerosis without evident tumor. A partial remission with a median duration of 7 months was assessed in 12 additional patients; thus the objective response rate (complete plus partial) was 30{\%} in non-resected patients; the response was not clearly related to stage, or to other prognostic factors. Of 32 patients who showed regression or stable disease, 28 had documented progression, which in 18 (64{\%}) was initially in extrahepatic sites. The median survival was 12 months, but it differed significantly according to stage. The presence of extrahepatic disease correlated with the worst prognosis. The survival of patients treated with a pump was no different from that of patients treated with a port. The study confirms that hepatic metastases from colorectal cancer can be controlled by arterial administration of FdUrd, but the benefit of treatment to survival is still to be demonstrated. The study also suggests that features of metastatic disease into and outside the liver can significantly affect survival. Thus, in evaluating the results of different treatments, the characteristics of metastases (i.e. the extent of hepatic involvement), should be taken into account.",
author = "R. Doci and P. Bignami and V. Quagliuolo and D. Civalleri and G. Simoni and M. Cosimelli and W. Craus and L. Gennari",
year = "1990",
language = "English",
volume = "3",
pages = "13--18",
journal = "Regional Cancer Treatment",
issn = "0935-0411",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Continuous hepatic arterial infusion with 5-fluorodeoxyuridine for treatment of colorectal metastases

AU - Doci, R.

AU - Bignami, P.

AU - Quagliuolo, V.

AU - Civalleri, D.

AU - Simoni, G.

AU - Cosimelli, M.

AU - Craus, W.

AU - Gennari, L.

PY - 1990

Y1 - 1990

N2 - 5-Fluorodeoxyuridine (FdUrd) was delivered into the hepatic artery by means of totally implantable devices in 61 patients with hepatic metastases from colorectal cancer. The metastatic disease was staged according to Genari's staging system. FdUrd was infused continuously for 14 days every 28 days at a dose of 0.3 mg kg-1 day-1. Hepatic resection was carried out in addition to the infusion in 12 patients. Toxic effects were observed in 24 (39%) patients; 4 of them developed biliary sclerosis. Device-related complications were reported in 37 (60%) patients; failures affected ports (86%) more frequently than pumps (32%); the median duration of pumps and ports was 28 and 9 months respectively. Among non-resected patients complete disappearance of liver metastases and normalization of carcinoembryonic antigen (CEA) were observed in 2 patients, 1 of whom died from biliary sclerosis without evident tumor. A partial remission with a median duration of 7 months was assessed in 12 additional patients; thus the objective response rate (complete plus partial) was 30% in non-resected patients; the response was not clearly related to stage, or to other prognostic factors. Of 32 patients who showed regression or stable disease, 28 had documented progression, which in 18 (64%) was initially in extrahepatic sites. The median survival was 12 months, but it differed significantly according to stage. The presence of extrahepatic disease correlated with the worst prognosis. The survival of patients treated with a pump was no different from that of patients treated with a port. The study confirms that hepatic metastases from colorectal cancer can be controlled by arterial administration of FdUrd, but the benefit of treatment to survival is still to be demonstrated. The study also suggests that features of metastatic disease into and outside the liver can significantly affect survival. Thus, in evaluating the results of different treatments, the characteristics of metastases (i.e. the extent of hepatic involvement), should be taken into account.

AB - 5-Fluorodeoxyuridine (FdUrd) was delivered into the hepatic artery by means of totally implantable devices in 61 patients with hepatic metastases from colorectal cancer. The metastatic disease was staged according to Genari's staging system. FdUrd was infused continuously for 14 days every 28 days at a dose of 0.3 mg kg-1 day-1. Hepatic resection was carried out in addition to the infusion in 12 patients. Toxic effects were observed in 24 (39%) patients; 4 of them developed biliary sclerosis. Device-related complications were reported in 37 (60%) patients; failures affected ports (86%) more frequently than pumps (32%); the median duration of pumps and ports was 28 and 9 months respectively. Among non-resected patients complete disappearance of liver metastases and normalization of carcinoembryonic antigen (CEA) were observed in 2 patients, 1 of whom died from biliary sclerosis without evident tumor. A partial remission with a median duration of 7 months was assessed in 12 additional patients; thus the objective response rate (complete plus partial) was 30% in non-resected patients; the response was not clearly related to stage, or to other prognostic factors. Of 32 patients who showed regression or stable disease, 28 had documented progression, which in 18 (64%) was initially in extrahepatic sites. The median survival was 12 months, but it differed significantly according to stage. The presence of extrahepatic disease correlated with the worst prognosis. The survival of patients treated with a pump was no different from that of patients treated with a port. The study confirms that hepatic metastases from colorectal cancer can be controlled by arterial administration of FdUrd, but the benefit of treatment to survival is still to be demonstrated. The study also suggests that features of metastatic disease into and outside the liver can significantly affect survival. Thus, in evaluating the results of different treatments, the characteristics of metastases (i.e. the extent of hepatic involvement), should be taken into account.

UR - http://www.scopus.com/inward/record.url?scp=0025110180&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025110180&partnerID=8YFLogxK

M3 - Article

VL - 3

SP - 13

EP - 18

JO - Regional Cancer Treatment

JF - Regional Cancer Treatment

SN - 0935-0411

IS - 1

ER -